Early Access

Early Access Programs are country-specific regulatory tools that allow a drug to be available on the market before its official launch, providing that it fulfils specific criteria. Despite potential significant advantages of these programs, many pharma/biotech companies remain unaware of the possibilities available in Europe.

In addition, even amongst the informed minority, many assume - wrongly - that an EAP will be too risky, too complicated or too costly to consider. “Reaching new patients in new markets quicker”